JP2007502295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502295A5 JP2007502295A5 JP2006523384A JP2006523384A JP2007502295A5 JP 2007502295 A5 JP2007502295 A5 JP 2007502295A5 JP 2006523384 A JP2006523384 A JP 2006523384A JP 2006523384 A JP2006523384 A JP 2006523384A JP 2007502295 A5 JP2007502295 A5 JP 2007502295A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- heterocyclyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims 26
- 125000003118 aryl group Chemical group 0.000 claims 23
- 125000003710 aryl alkyl group Chemical group 0.000 claims 22
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims 16
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 16
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 15
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 15
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 14
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 12
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 9
- 125000004429 atom Chemical group 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 7
- 125000004434 sulfur atom Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000002619 bicyclic group Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- -1 resolved enantiomers Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- FOVAPSHEBWJWGL-UHFFFAOYSA-N 1-[4-(3-chlorophenyl)-1-[3-(dimethylamino)propyl]piperidin-4-yl]propan-1-one;dihydrochloride Chemical compound Cl.Cl.C=1C=CC(Cl)=CC=1C1(C(=O)CC)CCN(CCCN(C)C)CC1 FOVAPSHEBWJWGL-UHFFFAOYSA-N 0.000 claims 1
- IVJNVMJPCBIFTA-UHFFFAOYSA-N 2-methylquinazoline-4,6-diamine Chemical compound C1=C(N)C=CC2=NC(C)=NC(N)=C21 IVJNVMJPCBIFTA-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 0 CCC(C)(*)N=*(NC)N(*)*(C)=N Chemical compound CCC(C)(*)N=*(NC)N(*)*(C)=N 0.000 description 11
- LNNFFEQNOYDBLO-UHFFFAOYSA-N C(c1ncccc1)Oc(cc1)c(C2[IH]C2)cc1Nc(c1c2)ncnc1ccc2NC1=NC(CNC2)C2O1 Chemical compound C(c1ncccc1)Oc(cc1)c(C2[IH]C2)cc1Nc(c1c2)ncnc1ccc2NC1=NC(CNC2)C2O1 LNNFFEQNOYDBLO-UHFFFAOYSA-N 0.000 description 1
- NTOIUWIFSFVQJQ-IPPBACCNSA-N CC(C1)C(Oc2ccccc2)=CC=C1Nc1ncnc2c1cc(/C=N/NC(COC)=N)cc2 Chemical compound CC(C1)C(Oc2ccccc2)=CC=C1Nc1ncnc2c1cc(/C=N/NC(COC)=N)cc2 NTOIUWIFSFVQJQ-IPPBACCNSA-N 0.000 description 1
- PXFBJRJPCQFUQY-UHFFFAOYSA-N CC(N)OCC(CO)(CO)N Chemical compound CC(N)OCC(CO)(CO)N PXFBJRJPCQFUQY-UHFFFAOYSA-N 0.000 description 1
- RVDBLABCOYZBMV-UHFFFAOYSA-N CC1(CO)N=C(Nc(cc23)ccc2ncnc3Nc(cc2)cc(Cl)c2OCc2cccc(F)c2)OC1 Chemical compound CC1(CO)N=C(Nc(cc23)ccc2ncnc3Nc(cc2)cc(Cl)c2OCc2cccc(F)c2)OC1 RVDBLABCOYZBMV-UHFFFAOYSA-N 0.000 description 1
- GUXJXWKCUUWCLX-UHFFFAOYSA-N CC1=NCCO1 Chemical compound CC1=NCCO1 GUXJXWKCUUWCLX-UHFFFAOYSA-N 0.000 description 1
- KLRJZHCELLGMCB-KLPHOBTLSA-N CC1C=C(/C=N/NC(C)=N)C=C2C(Nc(cc3Cl)ccc3OCc3cccc(F)c3)=NC=NC12 Chemical compound CC1C=C(/C=N/NC(C)=N)C=C2C(Nc(cc3Cl)ccc3OCc3cccc(F)c3)=NC=NC12 KLRJZHCELLGMCB-KLPHOBTLSA-N 0.000 description 1
- DKGHBASAZOGTAB-UHFFFAOYSA-N CC1N=C(Nc(cc2)cc3c2ncnc3Nc(cc2)cc(Cl)c2OCc2ccccn2)OC1 Chemical compound CC1N=C(Nc(cc2)cc3c2ncnc3Nc(cc2)cc(Cl)c2OCc2ccccn2)OC1 DKGHBASAZOGTAB-UHFFFAOYSA-N 0.000 description 1
- RUBJWKNIOKHRAC-UHFFFAOYSA-N CC1OC(Nc(cc2)cc3c2ncnc3Nc(cc2Cl)ccc2OCc2ccccn2)=NC1 Chemical compound CC1OC(Nc(cc2)cc3c2ncnc3Nc(cc2Cl)ccc2OCc2ccccn2)=NC1 RUBJWKNIOKHRAC-UHFFFAOYSA-N 0.000 description 1
- ZOQVYYINLXDVAA-UHFFFAOYSA-N CC1OC(Nc(cc23)ccc2N=CNC3Nc(cc2)cc(C)c2OC2=CNC(C)C=C2)=NC1 Chemical compound CC1OC(Nc(cc23)ccc2N=CNC3Nc(cc2)cc(C)c2OC2=CNC(C)C=C2)=NC1 ZOQVYYINLXDVAA-UHFFFAOYSA-N 0.000 description 1
- GIVFIMJOKVOQDT-UHFFFAOYSA-N CC1OC(Nc(cc23)ccc2ncnc3Nc(cc2)cc(Cl)c2OCc2ncc[s]2)NC1 Chemical compound CC1OC(Nc(cc23)ccc2ncnc3Nc(cc2)cc(Cl)c2OCc2ncc[s]2)NC1 GIVFIMJOKVOQDT-UHFFFAOYSA-N 0.000 description 1
- VTSUMCFFGMUODS-KLPHOBTLSA-N COCC(N/N=C/c(cc1)cc2c1ncnc2Nc(cc1Cl)ccc1OCc1cccc(F)c1)=N Chemical compound COCC(N/N=C/c(cc1)cc2c1ncnc2Nc(cc1Cl)ccc1OCc1cccc(F)c1)=N VTSUMCFFGMUODS-KLPHOBTLSA-N 0.000 description 1
- QZGIWJNNXZVDII-UHFFFAOYSA-N Cc(cc(cc1)Nc(c2c3)ncnc2ccc3NC2=NCCO2)c1Oc1ccc(C)nc1 Chemical compound Cc(cc(cc1)Nc(c2c3)ncnc2ccc3NC2=NCCO2)c1Oc1ccc(C)nc1 QZGIWJNNXZVDII-UHFFFAOYSA-N 0.000 description 1
- LFKSHLJVZXWZBV-UHFFFAOYSA-N Cc(cc(cc1)Nc2ncnc(cc3)c2cc3NC2=NC(COC3)C3O2)c1OCc1ncc[s]1 Chemical compound Cc(cc(cc1)Nc2ncnc(cc3)c2cc3NC2=NC(COC3)C3O2)c1OCc1ncc[s]1 LFKSHLJVZXWZBV-UHFFFAOYSA-N 0.000 description 1
- YQTHNULRNIAONX-UHFFFAOYSA-N Cc(cc(cc1)Nc2ncnc(cc3)c2cc3NC2=NC(COC3)C3O2)c1Oc1cnc(C)cc1 Chemical compound Cc(cc(cc1)Nc2ncnc(cc3)c2cc3NC2=NC(COC3)C3O2)c1Oc1cnc(C)cc1 YQTHNULRNIAONX-UHFFFAOYSA-N 0.000 description 1
- QIQNYHYMERTSPD-UHFFFAOYSA-N Cc1cc(NC2=NC=NC3C=CC(NC4=NCC5(CCOCC5)O4)=CC23)ccc1Oc1ccc(C)nc1 Chemical compound Cc1cc(NC2=NC=NC3C=CC(NC4=NCC5(CCOCC5)O4)=CC23)ccc1Oc1ccc(C)nc1 QIQNYHYMERTSPD-UHFFFAOYSA-N 0.000 description 1
- PVFIWCZYIRQZSL-UHFFFAOYSA-N Clc(cc(cc1)Nc(c2c3)ncnc2ccc3NC2=NC(COC3)C3O2)c1OCc1ncc[s]1 Chemical compound Clc(cc(cc1)Nc(c2c3)ncnc2ccc3NC2=NC(COC3)C3O2)c1OCc1ncc[s]1 PVFIWCZYIRQZSL-UHFFFAOYSA-N 0.000 description 1
- CWZISLULKPYASC-UHFFFAOYSA-N Clc(cc(cc1)Nc(c2c3)ncnc2ccc3NC2=NCC3(CCOCC3)O2)c1OCc1ncc[s]1 Chemical compound Clc(cc(cc1)Nc(c2c3)ncnc2ccc3NC2=NCC3(CCOCC3)O2)c1OCc1ncc[s]1 CWZISLULKPYASC-UHFFFAOYSA-N 0.000 description 1
- UDCKLYWMFGBYSA-UHFFFAOYSA-N Clc(cc(cc1)Nc(c2c3)ncnc2ccc3NC2=NCCO2)c1OCc1ncc[s]1 Chemical compound Clc(cc(cc1)Nc(c2c3)ncnc2ccc3NC2=NCCO2)c1OCc1ncc[s]1 UDCKLYWMFGBYSA-UHFFFAOYSA-N 0.000 description 1
- GINSUBFDDIACIY-UHFFFAOYSA-N Clc(cc(cc1)Nc2ncnc(cc3)c2cc3NC2=NC(CNC3)C3O2)c1OCc1ncc[s]1 Chemical compound Clc(cc(cc1)Nc2ncnc(cc3)c2cc3NC2=NC(CNC3)C3O2)c1OCc1ncc[s]1 GINSUBFDDIACIY-UHFFFAOYSA-N 0.000 description 1
- WJTSFUSWESMJEP-UHFFFAOYSA-N Clc(cc(cc1)Nc2ncnc(cc3)c2cc3NC2=NCCO2)c1OCc1ccccn1 Chemical compound Clc(cc(cc1)Nc2ncnc(cc3)c2cc3NC2=NCCO2)c1OCc1ccccn1 WJTSFUSWESMJEP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/642,440 US7501427B2 (en) | 2003-08-14 | 2003-08-14 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US10/642,440 | 2003-08-14 | ||
| US55171804P | 2004-03-10 | 2004-03-10 | |
| US60/551,718 | 2004-03-10 | ||
| PCT/US2004/026235 WO2005016346A1 (en) | 2003-08-14 | 2004-08-10 | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007502295A JP2007502295A (ja) | 2007-02-08 |
| JP2007502295A5 true JP2007502295A5 (enExample) | 2007-09-27 |
| JP4828421B2 JP4828421B2 (ja) | 2011-11-30 |
Family
ID=34198338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523384A Expired - Lifetime JP4828421B2 (ja) | 2003-08-14 | 2004-08-10 | 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US7452895B2 (enExample) |
| EP (1) | EP1660090B1 (enExample) |
| JP (1) | JP4828421B2 (enExample) |
| KR (2) | KR101028952B1 (enExample) |
| CN (3) | CN103772373B (enExample) |
| AR (1) | AR045378A1 (enExample) |
| AU (1) | AU2004264937B2 (enExample) |
| BR (1) | BRPI0413565B8 (enExample) |
| CA (1) | CA2535614C (enExample) |
| CL (1) | CL2004002066A1 (enExample) |
| CY (1) | CY1113992T1 (enExample) |
| DK (1) | DK1660090T3 (enExample) |
| ES (1) | ES2399427T3 (enExample) |
| IL (1) | IL173593A (enExample) |
| IS (1) | IS8288A (enExample) |
| MX (1) | MXPA06001767A (enExample) |
| NO (1) | NO336275B1 (enExample) |
| NZ (1) | NZ545459A (enExample) |
| PL (1) | PL1660090T3 (enExample) |
| PT (1) | PT1660090E (enExample) |
| RU (1) | RU2350605C2 (enExample) |
| TW (1) | TWI353982B (enExample) |
| WO (1) | WO2005016346A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7488823B2 (en) * | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| US7501427B2 (en) | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| NZ545459A (en) | 2003-08-14 | 2009-12-24 | Array Biopharma Inc | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| DE602006009968D1 (de) | 2005-11-15 | 2009-12-03 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| CN114886853A (zh) | 2011-10-14 | 2022-08-12 | 阵列生物制药公司 | ErbB2(HER2)抑制剂的固态分散体 |
| KR20200003245A (ko) | 2011-10-14 | 2020-01-08 | 어레이 바이오파마 인크. | 선택적인 herb2 저해제인 arry-380의 다형체 및 이를 함유하는 약제학적 조성물 |
| TR201808450T4 (tr) | 2012-03-23 | 2018-07-23 | Array Biopharma Inc | Beyin kanserinin tedavisinde kullanılmaya yönelik amorf katı dispersiyon. |
| CN108135901A (zh) * | 2015-09-04 | 2018-06-08 | 亚狮康私人有限公司 | 胆管癌的治疗 |
| JP2019514864A (ja) * | 2016-04-21 | 2019-06-06 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 肝癌の治療方法 |
| GB201611580D0 (en) * | 2016-07-01 | 2016-08-17 | Aslan Pharmaceuticals Pte Ltd | Method |
| CN106349230A (zh) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
| CN106279135A (zh) * | 2016-08-09 | 2017-01-04 | 浙江医药高等专科学校 | 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂 |
| CN106317039A (zh) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途 |
| CN106349231A (zh) * | 2016-08-09 | 2017-01-25 | 浙江医药高等专科学校 | 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂 |
| CN106317040A (zh) * | 2016-08-09 | 2017-01-11 | 浙江医药高等专科学校 | 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途 |
| WO2018038684A1 (en) | 2016-08-26 | 2018-03-01 | Agency For Science, Technology And Research | Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof |
| WO2018160138A1 (en) | 2017-03-02 | 2018-09-07 | Aslan Pharmaceuticals Pte Ltd | Dhodh inhibitor for treating haematological cancer |
| EP3615067A1 (en) | 2017-04-28 | 2020-03-04 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| WO2018222134A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| WO2018222135A1 (en) | 2017-06-02 | 2018-12-06 | Aslan Pharmaceuticals Pte Ltd | Cancer therapy |
| ES2971927T3 (es) | 2018-09-18 | 2024-06-10 | Hoffmann La Roche | Derivados de quinazolina como agentes antitumorales |
| AU2019359036A1 (en) * | 2018-10-09 | 2021-06-03 | Aslan Pharmaceuticals Pte Ltd | Malonate salt of varlitinib |
| CN111499622B (zh) * | 2019-07-08 | 2023-06-06 | 山东省科学院菏泽分院 | 一种治疗胆管癌的药物的制备方法 |
| TW202214641A (zh) | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| CA3225045A1 (en) | 2021-06-26 | 2022-12-29 | Array Biopharma Inc. | Her2 mutation inhibitors |
| WO2023081637A1 (en) * | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| TW202345816A (zh) * | 2022-03-28 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含氮雜環類化合物、其製備方法及其在醫藥上的應用 |
| TW202530231A (zh) * | 2023-09-27 | 2025-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 喹唑啉衍生物的可藥用鹽、其結晶形式及用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2583774A (en) | 1948-04-30 | 1952-01-29 | Merck & Co Inc | Vitamin b6 derivatives |
| BE795970A (fr) | 1972-02-29 | 1973-08-27 | Pfizer | Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant |
| US5204348A (en) | 1988-10-06 | 1993-04-20 | Mitsui Toatsu Chemicals Inc. | Heterocyclic compounds and anticancer-drug potentiaters conaining them as effective components |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (enExample) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| GB9424233D0 (en) | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
| EP0817775B1 (en) * | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| US6225318B1 (en) | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| WO1999024440A1 (en) | 1997-11-11 | 1999-05-20 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| JP2002505288A (ja) | 1998-03-02 | 2002-02-19 | コセンシス，インコーポレイテッド | 置換キナゾリンおよびアナログならびにそれらの使用 |
| US6017922A (en) | 1998-05-18 | 2000-01-25 | U.S. Bioscience, Inc. | Thermally stable trimetrexates and processes for producing the same |
| EA003786B1 (ru) | 1998-11-19 | 2003-10-30 | Варнер Ламберт Компани | N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ |
| HUP0105113A3 (en) | 1999-01-13 | 2004-11-29 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds |
| PL199802B1 (pl) * | 1999-02-10 | 2008-10-31 | Astrazeneca Ab | Pochodne chinazoliny, sposoby ich wytwarzania, ich kompozycje farmaceutyczne i ich zastosowania |
| BR0014133A (pt) | 1999-09-21 | 2002-06-11 | Astrazeneca Ab | Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica |
| GB9922171D0 (en) * | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| RU2260586C2 (ru) | 2000-02-17 | 2005-09-20 | Бристол-Маерс Сквибб Ко. | Лиганды тироидного рецептора - производные анилина |
| JP2003535867A (ja) | 2000-06-06 | 2003-12-02 | ファイザー プロダクツ インコーポレイテッド | 抗癌剤として有用なチオフェン誘導体 |
| HUP0301120A2 (hu) | 2000-06-22 | 2003-08-28 | Pfizer Products Inc. | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények |
| KR100815681B1 (ko) | 2000-06-30 | 2008-03-20 | 글락소 그룹 리미티드 | 퀴나졸린 디토실레이트 염 화합물 |
| WO2003015778A1 (en) | 2001-08-17 | 2003-02-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US7169788B2 (en) | 2001-10-30 | 2007-01-30 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| ATE423104T1 (de) * | 2001-11-03 | 2009-03-15 | Astrazeneca Ab | Quinazolin derivate als antitumor-mittel |
| JP4498741B2 (ja) * | 2001-12-24 | 2010-07-07 | アストラゼネカ アクチボラグ | オーロラキナーゼ阻害剤としての置換キナゾリン誘導体 |
| US7488823B2 (en) | 2003-11-10 | 2009-02-10 | Array Biopharma, Inc. | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors |
| CA2514479A1 (en) | 2003-01-23 | 2004-08-05 | T.K. Signal Ltd. | Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof |
| PE20040945A1 (es) | 2003-02-05 | 2004-12-14 | Warner Lambert Co | Preparacion de quinazolinas substituidas |
| MXPA05012839A (es) | 2003-05-27 | 2006-05-17 | Pfizer Prod Inc | Quinazolinas y pirido[3,4-d] pirimidinas como inhibidores de receptores tirosina quinasa. |
| NZ545459A (en) | 2003-08-14 | 2009-12-24 | Array Biopharma Inc | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| US7501427B2 (en) * | 2003-08-14 | 2009-03-10 | Array Biopharma, Inc. | Quinazoline analogs as receptor tyrosine kinase inhibitors |
| KR20080014144A (ko) | 2003-08-18 | 2008-02-13 | 화이자 프로덕츠 인크. | ｅｒｂＢ２ 항암제에 대한 투약 스케쥴 |
| MXPA06005024A (es) | 2003-11-06 | 2006-07-06 | Pfizer Prod Inc | Combinaciones de inhibidor de erbb2 selectivo/anticuerpos anti-erbb en el tratamiento del cancer. |
| KR100735639B1 (ko) | 2004-12-29 | 2007-07-04 | 한미약품 주식회사 | 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법 |
| DE602006009968D1 (de) | 2005-11-15 | 2009-12-03 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i-rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
-
2004
- 2004-08-10 NZ NZ545459A patent/NZ545459A/en not_active IP Right Cessation
- 2004-08-10 BR BRPI0413565A patent/BRPI0413565B8/pt not_active IP Right Cessation
- 2004-08-10 PL PL04780990T patent/PL1660090T3/pl unknown
- 2004-08-10 KR KR1020107000942A patent/KR101028952B1/ko not_active Expired - Lifetime
- 2004-08-10 RU RU2006103493/04A patent/RU2350605C2/ru active
- 2004-08-10 ES ES04780990T patent/ES2399427T3/es not_active Expired - Lifetime
- 2004-08-10 JP JP2006523384A patent/JP4828421B2/ja not_active Expired - Lifetime
- 2004-08-10 KR KR1020067003060A patent/KR100953246B1/ko not_active Expired - Lifetime
- 2004-08-10 PT PT47809900T patent/PT1660090E/pt unknown
- 2004-08-10 MX MXPA06001767A patent/MXPA06001767A/es active IP Right Grant
- 2004-08-10 CA CA002535614A patent/CA2535614C/en not_active Expired - Lifetime
- 2004-08-10 EP EP04780990A patent/EP1660090B1/en not_active Expired - Lifetime
- 2004-08-10 US US10/914,974 patent/US7452895B2/en not_active Expired - Lifetime
- 2004-08-10 DK DK04780990.0T patent/DK1660090T3/da active
- 2004-08-10 CN CN201310581100.3A patent/CN103772373B/zh not_active Expired - Lifetime
- 2004-08-10 CN CN201110283526.1A patent/CN102432552B/zh not_active Expired - Lifetime
- 2004-08-10 AU AU2004264937A patent/AU2004264937B2/en active Active
- 2004-08-10 WO PCT/US2004/026235 patent/WO2005016346A1/en not_active Ceased
- 2004-08-10 CN CN201310428856.4A patent/CN103664802B/zh not_active Expired - Lifetime
- 2004-08-13 AR ARP040102929A patent/AR045378A1/es active IP Right Grant
- 2004-08-13 CL CL200402066A patent/CL2004002066A1/es unknown
- 2004-08-13 TW TW093124336A patent/TWI353982B/zh not_active IP Right Cessation
-
2006
- 2006-02-07 IS IS8288A patent/IS8288A/is unknown
- 2006-02-07 IL IL173593A patent/IL173593A/en active IP Right Grant
- 2006-03-13 NO NO20061171A patent/NO336275B1/no unknown
-
2008
- 2008-10-10 US US12/249,421 patent/US8278314B2/en active Active
-
2013
- 2013-02-08 CY CY20131100122T patent/CY1113992T1/el unknown